NCT01585272View on ClinicalTrials.gov

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Alzheimer's Dementia
Interventions
DRUG

ENA713

Trial Locations (4)

112

Novartis Investigative Site, Taipei

10002

Novartis Investigative Site, Taipei

40447

Novartis Investigative Site, Taichung

Unknown

Novartis Investigative Site, Taichung

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY